Newsroom

Download PDF CAMBRIDGE, MA October 23, 2006 – AVEO Pharmaceuticals, Inc. (AVEO), a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that it has begun enrolling patients in a Phase I clinical study for AV-412, a next generation oral tyrosine kinase inhibitor of EGFR/HER2.  The open-label, sequential dose escalation study

Download PDF – Contract Follows Successful Human Engineering™ of AV-299 – Berkeley, CA and Cambridge, MA — September 28th, 2006 – Xoma Ltd. (Nasdaq: XOMA) and AVEO Pharmaceuticals, Inc. (AVEO) today announced a $6 million agreement for XOMA to manufacture and supply AV-299, AVEO’s novel anti-HGF antibody, in support of early clinical trials.  The companies also

Download PDF CAMBRIDGE, MA (September 27, 2006) – The Web Marketing Association (“WMA”) today announced that it has awarded its “Pharmaceutical Industry Standard of Excellence” WebAward for 2006 to AVEO Pharmaceuticals – a biopharmaceutical company focused on the discovery and development of novel cancer therapeutics. The website was designed, implemented, and launched in 2006 by Embarc,

Download PDF – Human Engineering™ Technology to Accelerate Development of Clinical Candidate – Berkeley, CA and Cambridge, MA — April 27, 2006 — XOMA Ltd. (Nasdaq: XOMA) and AVEO Pharmaceuticals, Inc. (AVEO) today announced an agreement for XOMA to utilize its Human Engineering™ (HE™) technology to humanize AV-299, AVEO’s novel anti-HGF monoclonal antibody.  For work conducted and

Download PDF – Human-in-Mouse (HIM) system represents breakthrough in modeling of human breast cancer –  – HIM system offers potential for significantly improved predictability in preclinical drug testing – CAMBRIDGE, MA April 4, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that is has

Download PDF – AV-412, a novel EGFR/HER2 kinase inhibitor, demonstrates potent anti-tumor activity against both Tarceva® and Iressa®-sensitive and resistant tumors – – AV-412 holds promise as a broader-acting EFGR/HER2 inhibitor – CAMBRIDGE, MA April 4, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today

Download PDF Palo Alto, Calif. – March 30, 2006 – Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), a leading debt and equity growth capital provider to technology and life science companies, announced on March 29, 2006 it provided $15.0 million of debt financing to AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development

Download PDF – Dr. Ryan’s Expertise in Translational Medicine a Key Addition as AVEO Moves its Portfolio of Novel Cancer Medicines Forward into the Clinic – CAMBRIDGE, MA March 30, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that John L. Ryan, Ph.D., M.D., has